BACKGROUND: The genes mutated in the cancer-prone syndrome, xeroderma pigmentosum (XP genes), have been well studied both biochemically and mechanistically. These genes are important components of the DNA nucleotide excision repair (NER) pathway, which protects against environmentally-induced cancers. XP genes are also downstream of the hereditary breast cancer syndrome gene, BRCA1, suggesting that XP genes may be important to hereditary forms of breast cancer as well. Although mutated XP genes are rare, polymorphic forms with potential functional deficiencies are common, and could pose a significant cancer risk in the general population. HYPOTHESIS: This study tested the hypothesis that common polymorphic variants of XP genes were associated with the risk of breast cancer among a population of women in Washington County, Maryland. METHODS: Five single nucleotide polymorphisms (SNPs) among four XP genes (XPC, XPD, XPF and XPG) were genotyped from DNA samples collected at baseline, and then analyzed by conditional logistic regression for association with the incidence of breast cancer. 321 cases were individually matched to 321 controls, by age and menopausal status. RESULTS: No significant associations were found between breast cancer risk and any of the XP genotypes. Odds ratios for all genotypes ranged from 0.61 to 1.14, and none were statistically significant. Adjustment and stratification for family history of breast cancer did not alter the findings. CONCLUSION: These results suggest that polymorphisms of XP genes are not likely to be significant risk factors for women within the general population. This study did not address, however, risks for subpopulations of women with high exposures to DNA damaging agents.
BACKGROUND: The genes mutated in the cancer-prone syndrome, xeroderma pigmentosum (XP genes), have been well studied both biochemically and mechanistically. These genes are important components of the DNA nucleotide excision repair (NER) pathway, which protects against environmentally-induced cancers. XP genes are also downstream of the hereditary breast cancer syndrome gene, BRCA1, suggesting that XP genes may be important to hereditary forms of breast cancer as well. Although mutated XP genes are rare, polymorphic forms with potential functional deficiencies are common, and could pose a significant cancer risk in the general population. HYPOTHESIS: This study tested the hypothesis that common polymorphic variants of XP genes were associated with the risk of breast cancer among a population of women in Washington County, Maryland. METHODS: Five single nucleotide polymorphisms (SNPs) among four XP genes (XPC, XPD, XPF and XPG) were genotyped from DNA samples collected at baseline, and then analyzed by conditional logistic regression for association with the incidence of breast cancer. 321 cases were individually matched to 321 controls, by age and menopausal status. RESULTS: No significant associations were found between breast cancer risk and any of the XP genotypes. Odds ratios for all genotypes ranged from 0.61 to 1.14, and none were statistically significant. Adjustment and stratification for family history of breast cancer did not alter the findings. CONCLUSION: These results suggest that polymorphisms of XP genes are not likely to be significant risk factors for women within the general population. This study did not address, however, risks for subpopulations of women with high exposures to DNA damaging agents.
Authors: Tasha R Smith; Edward A Levine; Rita I Freimanis; Steven A Akman; Glenn O Allen; Kimberly N Hoang; Wen Liu-Mares; Jennifer J Hu Journal: Carcinogenesis Date: 2008-08-13 Impact factor: 4.944
Authors: Shaid All Sahaba; Mohammad Abdur Rashid; Md Saiful Islam; Noor Ahmed Nahid; Mohd Nazmul Hasan Apu; Taposhi Nahid Sultana; Nusrat Islam Chaity; Md Mehedi Hasan; Mohammad Safiqul Islam Journal: Mol Biol Rep Date: 2021-11-26 Impact factor: 2.316
Authors: Preetha Rajaraman; Parveen Bhatti; Michele Morin Doody; Steven L Simon; Robert M Weinstock; Martha S Linet; Marvin Rosenstein; Marilyn Stovall; Bruce H Alexander; Dale L Preston; Alice J Sigurdson Journal: Int J Cancer Date: 2008-12-01 Impact factor: 7.396
Authors: Jing Shen; Marilie D Gammon; Mary Beth Terry; Susan L Teitelbaum; Sybil M Eng; Alfred I Neugut; Regina M Santella Journal: Eur J Cancer Date: 2007-11-28 Impact factor: 9.162